AT-02 is a fusion protein of humanized immunoglobulin G1 with a pan amyloid-reactive peptide that facilitates binding of the antibody to amyloid deposits and subsequent removal. The Food and Drug ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...

More than half of 95 centenarians had a low amyloid load and 9% had no amyloid, autopsy data showed. A third of centenarians had a high amyloid load comparable to Alzheimer's disease. Five ...

Piller is an investigative journalist for Science. In November 2022, Dennis Selkoe, a Harvard professor of neurologic diseases and among the most celebrated and prolific Alzheimer’s researchers, ...

Torie Bosch is the First Opinion editor at STAT. First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech ...

Reduced amyloid burden after treatment with the antiamyloid donanemab (Kisunla, Eli Lilly) correlated strongly with slower cognitive and functional decline in adults with early symptomatic Alzheimer’s ...

A recent study tests a new drug, gantenerumab on people with a genetically inherited form of Alzheimer’s disease. For people with this condition, dementia is almost inevitable. Gantenerumab helps ...

Medications like lecanemab (Leqembi) and donanemab (Kisunla) target amyloid plaques in the brain that build up due to Alzheimer’s disease. They may help slow disease progression for people in the ...

The new understanding of molecular events that drive the various forms of amyloidosis has led to the expansion of therapeutic options to prevent end-stage disease or even offer a cure, which has added ...

Amyloid heart disease occurs when amyloid fibrils build up in the heart, making it more difficult for the heart to pump blood around the body. Eventually, this can lead to heart failure. People can ...